Title: NHS and Psilocybin: The Controversy Over Psychedelic Depression Treatments

Larissa Hope credits psilocybin, the psychoactive compound found in magic mushrooms, with aiding her recovery from a severe mental health struggle. The narrative began when Hope, then 17 and beginning her acting career on the television series Skins, found that sudden fame triggered long-buried trauma. While conventional antidepressants failed to provide relief, a supervised dose of psilocybin proved transformative. Recalling the moment, Hope states, "When I experienced it, I burst out crying. It was the first time in my life I had ever felt a sense of belonging and safety in my body. I kept saying, 'I'm home, I'm home'." Nearly two decades later, she attributes her ability to overcome suicidal ideation to the combination of therapy and that initial psilocybin experience.

However, not all accounts are positive. Jules Evans, a university researcher, recounts a harrowing experience with LSD during his teenage years. Although taken recreatively at age 18, the substance induced a "deluded" state characterized by intense paranoia. "I believed that everyone was talking about me, criticising me, judging me. I thought, I've permanently damaged myself; I've permanently lost my mind," Evans explains. He describes it as the most frightening experience of his life. Evans now leads the Challenging Psychedelic Experiences Project, supporting individuals who suffer adverse effects from psychedelics. He notes that years after his own trip, he was diagnosed with post-traumatic stress disorder (PTSD) and continued to suffer from panic attacks and social anxiety.

These contrasting outcomes lie at the core of a pressing dilemma for healthcare providers, policymakers, and regulators: should medical professionals be permitted to prescribe magic mushrooms and other potentially therapeutic psychedelic substances?

This question has gained urgency following a wave of recent research indicating that psychedelic drugs may offer relief for depression, obsessive-compulsive disorder, trauma, PTSD, and various addictions, including those related to alcohol and gambling. Currently, the use of psychedelic medicine remains illegal outside of authorized clinical trials and research settings. Since 2022, over 20 trials have investigated these compounds for conditions such as addiction, PTSD, and depression. While many studies suggest therapeutic benefits, several have yielded mixed or inconclusive results, with only a handful showing no significant benefit on primary measures.

The UK’s medicines regulator is currently awaiting data from one of the largest psilocybin clinical trials, conducted by biotech firm Compass Pathways, expected later this year. This data will influence decisions on whether to ease strict regulations to allow psychedelic medicines to be used beyond the confines of research.

Prof Oliver Howes, chair of the Royal College of Psychiatrists' Psychopharmacology Committee, expresses optimism about psychedelics as a potential new class of psychiatric treatments for NHS patients. He highlights the critical need for improved mental health interventions, noting, "One of the key messages is that this is something we desperately need – more treatments and better treatments for mental health disorders." He adds that these drugs are compelling because they have demonstrated promise in small-scale studies and may act more rapidly than existing options. However, Howes urges restraint, emphasizing the necessity of robust evidence to avoid overstating their potential.

Caution is also advised by other experts. A report from the Royal College of Psychiatrists, released in September 2025, highlighted the potential risks associated with psychedelics. Medical professionals continue to stress that beyond being illegal, psychedelic drug use can pose significant health dangers.

The intersection of drug use and human civilization is ancient, with substances like magic mushrooms, opium, and cannabis historically utilized for both recreational and ritualistic purposes. By the 1960s and 1970s, LSD also

Source: BBC News Generated at: 2026-01-02 15:47:15 UTC